Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
• Treatments: Antihypertensive Agents; Carvedilol

Criteria

Inclusion Criteria:

• Male or female outpatients ≥ 19 years of age

• Mild to moderate essential hypertension: sDBP 90 ~ 109, sSBP 140 ~ 179

• Subjects who agree to participate in this sudy and give written informed consent

• Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study

Exclusion Criteria:

• The sitting DBP is more than 110mmHg or the sitting SBP over 180mmHg

• Patients with postural hypotension

• Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 3 times more than upper limit of normal)disease

• Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal

• Patients judged to have a history of alcohol or drug abuse by the investigator

• Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months

• Patients with uncontrolled diabetes mellitus

• Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons